Effect of Treatment for 12 Weeks With Rilapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, on Arterial Inflammation as Assessed With 18F-Fluorodeoxyglucose-Positron Emission Tomography Imaging

Tawakol, Ahmed; Singh, Parmanand; Rudd, James H.F.; Soffer, Joseph; Cai, Gengqian; Vucic, Esad; Brannan, Sarah P.; Tarka, Elizabeth; Shaddinger, Bonnie C.; Sarov‐Blat, Lea; Matthews, Paul M.; Subramanian, Sharath; Farkouh, Michael E.; Fayad, Zahi A.

doi:10.1016/j.jacc.2013.07.050

Cited by 76 publications

(92 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The plaques were assessed by a pathologist and a research physician blinded for the clinical and the 18 F-FDG PET findings. Inflammation was quantified using a modified version of the method used by Jander et al 3 The sections were evaluated with 1209 magnification and the percentage area of inflammatory cells 18 F-FDG uptake quantification was based on the SUV max of all the plaque-containing axial PET slices (A): Max SUV max = the single highest SUV max (B), mean SUV max = the mean of all plaque SUV max (C), MDS3 = the mean SUV max of the three contiguous slices centered on the slice with the highest SUV max (D), MDS5 = the mean SUV max of the five contiguous slices centered on the slice with the highest SUV max (E), and mean SUV max 4 = the mean SUV max of the four slices with highest SUV max within the plaque(F) (based on a figure by Tawakol et al 32 ). assessment on selected sections from this study cohort and found that the amount of inflammatory cells was in the same 5% category at both assessments for 73% of the sections (Kappa = 0.73).…”

Section: Endarterectomy and Histological Analysismentioning

confidence: 99%

18F-FDG PET/CT for the quantification of inflammation in large carotid artery plaques

Johnsrud

Skagen

Seierstad

et al. 2019

Journal of Nuclear Cardiology

View full text Add to dashboard Cite

Background. There is currently no consensus on the methodology for quantification of 18 F-FDG uptake in inflammation in atherosclerosis. In this study, we explore different methods for quantification of 18 F-FDG uptake in carotid atherosclerotic plaques and correlate the uptake values to histological assessments of inflammation.Methods and Results. Forty-four patients with atherosclerotic stenosis ‡70% of the internal carotid artery underwent 18 F-FDG PET/CT. Maximum standardized uptake values (SUV max ) from all plaque-containing slices were collected. SUV max for the single highest and the mean of multiple slices with and without blood background correction (by subtraction (cSUV) or by division (target-to-background ratio (TBR)) were calculated. Following endarterectomy 30 plaques were assessed histologically. The length of the plaques at CT was 6-32 mm. The 18 F-FDG uptake in the plaques was 1.15-2.66 for uncorrected SUVs, 1.16-3.19 for TBRs, and 0.20-1.79 for cSUVs. There were significant correlations between the different uptake values (r 5 0.57-0.99, P < 0.001). Methods with and without blood background correction showed similar, moderate correlations to the amount of inflammation assessed at histology (r 5 0.44-0.59, P < 0.02).Conclusions. In large stenotic carotid plaques, 18 F-FDG uptake reflects the inflammatory status as assessed at histology. Increasing number of PET slices or background correction did not change the correlation. (J Nucl Cardiol 2017)

show abstract

Section: Endarterectomy and Histological Analysismentioning

confidence: 99%

18F-FDG PET/CT for the quantification of inflammation in large carotid artery plaques

Johnsrud

Skagen

Seierstad

et al. 2019

Journal of Nuclear Cardiology

View full text Add to dashboard Cite

show abstract

“…Molecular imaging is a complementary approach that provides new insights into mechanisms of atherosclerosis progression and complications. For larger arteries (carotid, iliac, aorta), 18 F-FDG PET imaging currently predominates to detect plaque inflammatory cells (macrophages). In the smaller-sized coronary arteries, 18 F-sodium fluoride ( 18 F-NaF) PET and highresolution intravascular near-infrared fluorescence (NIRF) molecular imaging are emerging new approaches to image plaque mineralization and inflammation (e.g., protease activity), respectively.…”

Section: Atherosclerosis Backgroundmentioning

confidence: 99%

“…In atherosclerosis, the most widely used PET tracer is 18 F-FDG, a glucose analog consumed by metabolically active cells. 18 F-FDG possesses a 110-min half-life and maximum 2.4-mm positron range.…”

Section: F-fdg Petmentioning

confidence: 99%

Metabolic and Molecular Imaging of Atherosclerosis and Venous Thromboembolism

et al. 2017

Self Cite

View full text Add to dashboard Cite

Prediction is very difficult, especially if it's about the future. -Niels BohrMetabolic and molecular imaging continues to advance our understanding of vascular disease pathophysiology. At present, 18 F-FDG PET imaging is the most widely used clinical tool for metabolic and molecular imaging of atherosclerosis. However, novel nuclear tracers and intravascular optical near-infrared fluorescence imaging catheters are emerging to assess new biologic targets in vivo and in coronary arteries. This review highlights current metabolic and molecular imaging clinical and near-clinical applications within atherosclerosis and venous thromboembolism, and explores the potential for metabolic and molecular imaging to affect patient-level risk prediction and disease treatment.

show abstract

“…[144][145][146][147] La señal vascular cuantitativa de PET FDG ha sido ampliamente utilizada como un objetivo subrogado para probar los efectos de drogas antiinflamatorias en los estudios clínicos. [148][149][150][151][152][153][154][155] La PET con FDG se está usando activamente como un objetivo subrogado en muchos estudios en curso de ateroesclerosis. Más recientemente, otros agentes de imágenes novedosos dirigidos se han utilizado con PET para caracterizar la inflamación 134,156-160 y otros aspectos de la biología de la placa que incluyen la neoangiogénesis 161 y microcalcificación, 162 y también en complicaciones de la ateroesclerosis 163 en animales experimentales y seres humanos.…”

Section: Imágenes De Infarto De Miocardiounclassified

The Future of Cardiovascular Imaging

2016

View full text Add to dashboard Cite

O ver the past 2 decades, we have witnessed an explosive expansion in the armamentarium of noninvasive and invasive imaging technologies capable of providing detailed information about the structure and function of the heart and vasculature. Many of these technologies are integrative (eg, positron emission tomography and computed tomography, positron emission tomography and MRI), thereby compounding the unique strengths of the component technologies to achieve unprecedented improvements to our ability to diagnose disease, improve patient care, and advance biomedical research. In addition, the miniaturization of imaging devices with dramatic increases in sensitivity and spatial resolution, coupled with the development of quantitative molecular imaging approaches for evaluating physiology and pathobiology at the cellular and molecular levels, provides a unique platform for a new era in diagnostic imaging. The crucial role of imaging in early phenotyping of disease, risk assessment, and management guidance is expanding rapidly in ways previously thought unrealistic.Along with clinical, molecular, and genomewide association studies, structural and functional quantitative imaging already plays a critical role in phenotyping cardiovascular disease. Unique strengths of imaging phenotyping include its ability to provide precise, organ-specific anatomic localization and quantification of disease traits, to demonstrate and quantify involvement of other organs in cardiac disease, to provide an opportunity to investigate the time course of disease-specific molecular events in vivo, and to track their response to therapy. In so doing, quantitative structural and functional imaging can provide a nuanced description of disease burden (eg, atherosclerosis, myocarditis), disease subtypes (eg, amyloidosis), and, importantly, the relationship between the specific phenotype and outcomes, thereby informing treatment strategies and allowing more personalized approaches to patient management.Our objectives for this article are to (1) provide a viewpoint regarding the evolving role of cardiovascular imaging in biomedical research and clinical practice, (2) discuss the challenges associated with clinical translation of imaging innovations and the opportunities for multimodality imaging in the changing paradigm of value-based medicine, and (3) briefly outline future challenges and opportunities including the requirements for training future generations of imaging scientists and clinical specialists. Unlike traditional reviews that provide a detailed discussion of the role of 1 or more imaging modalities in cardiovascular (CV) disease, our discussion will focus on the potential role of imaging in what we believe are key areas of the translational highway with specific examples on how structural and functional imaging may contribute to scientific discovery, diagnosis, risk stratification, and patient management in each of those areas. Redefining the Role of Imaging Across the Continuum of Biomedical Research and Clinical Practice Translati...

show abstract

Effect of Treatment for 12 Weeks With Rilapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, on Arterial Inflammation as Assessed With 18F-Fluorodeoxyglucose-Positron Emission Tomography Imaging

Cited by 76 publications

References 5 publications

18F-FDG PET/CT for the quantification of inflammation in large carotid artery plaques

18F-FDG PET/CT for the quantification of inflammation in large carotid artery plaques

Metabolic and Molecular Imaging of Atherosclerosis and Venous Thromboembolism

The Future of Cardiovascular Imaging

Contact Info

Product

Resources

About